STRO SEC Filings: 8-K, 10-Q, S-3 & 424B – Sutro Biopharma

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 23, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Sutro Biopharma Reports Q2 2026 Financial Results and Positive Early Clinical Data for STRO-004

Aug 12, 2026

8-K

Sutro Biopharma, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 8, 2026

8-K

Sutro Biopharma Reports Q1 2026 Financial Results and Pipeline Progress

May 14, 2026

8-K

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

Mar 23, 2026

8-K

Sutro Biopharma Advances Multiple ADC Programs with Promising Data

Feb 10, 2026

8-K

Sutro Biopharma Regains Compliance with Nasdaq Listing Rules

Dec 17, 2025

Prospectus

TYPE

HEADLINE

FILED AT

424B3

April 2026 ATM | Offering amount: $100,000,000 | Bank: TD Securities (USA) LLC

Apr 1, 2026

424B5

REGISTERED OFFERING

Feb 10, 2026

424B5

OFFERING | Shares amount: 14,478,764 | Share price: $5.18 | Offering amount: $74,999,998.00

Apr 2, 2024

424B5

Up to $100,000,000 Common Stock PROSPECTUS SUPPLEMENT Jefferies February 9, 2024

Feb 9, 2024

424B5

6,000,000 Shares-

Dec 9, 2020

424B5

5,000,000 Shares-

Dec 7, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-3

March 2026 SHELF and ATM

Mar 23, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 23, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 30, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 27, 2025

S-8

Registration

Feb 27, 2024

S-3

SHELF | Offering amount: $300,000,000.00 EFFECTIVE

Nov 13, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 22, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 22, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 14, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 17, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

NEWCoastlands Capital LP (Filed by)

Nov 9, 2026

Gerber Hans-Peter (Reporting)

Sep 22, 2026

SCHEDULE 13G/A

PERCEPTIVE ADVISORS LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

Point72 Asset Management, L.P. (Filed by)

Aug 14, 2026

SCHEDULE 13G

BlackRock, Inc. (Filed by)

Jul 30, 2026

Wigginton Jon Marc (Reporting)

Jun 9, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 2, 2026

CORRESP

Form CORRESP - Correspondence

Mar 30, 2026

LETTER

Form UPLOAD - SEC-generated letter

Mar 27, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 22, 2023

CORRESP

Form CORRESP - Correspondence

Nov 17, 2023

LETTER

Form UPLOAD - SEC-generated letter

Nov 16, 2023

Sutro Biopharma, Inc. STRO · SEC Filings